ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative RD Trends for ...
| ZVSADelisted Stock | 0.15 0.01 6.25% |
About 61% of ZyVersa Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading ZyVersa Therapeutics stock suggests that many investors are alarmed at this time. The current market sentiment, together with ZyVersa Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use ZyVersa Therapeutics stock news signals to limit their universe of possible portfolio assets.
ZyVersa |
ZyVersa Therapeutics is advancing its Inflammasome ASC Inhibitor IC 100 with key milestones set for 2025. The global anti-inflammatory biologics
Read at gurufocus.com
 |
ZyVersa Therapeutics Fundamental Analysis
We analyze ZyVersa Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ZyVersa Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ZyVersa Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
ZyVersa Therapeutics is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
ZyVersa Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ZyVersa Therapeutics stock to make a market-neutral strategy. Peer analysis of ZyVersa Therapeutics could also be used in its relative valuation, which is a method of valuing ZyVersa Therapeutics by comparing valuation metrics with similar companies.
Peers
ZyVersa Therapeutics Related Equities
| DRMA | Dermata Therapeutics | 9.46 | ||||
| SMX | SMX Public | 7.20 | ||||
| CNSP | Cns Pharmaceuticals | 2.47 | ||||
| IMMX | Immix Biopharma | 4.15 | ||||
| FOXO | FOXO Technologies | 6.25 | ||||
| SONN | Sonnet Biotherapeutics | 15.36 |
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in ZyVersa Stock
If you are still planning to invest in ZyVersa Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ZyVersa Therapeutics' history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |